Faricimab Cost-Effectiveness Model Inputs for Diabetic Macular Edema in China

11528129 bytes of supplementary materials support a cost-effectiveness analysis of faricimab for diabetic macular edema in China. The dataset contains nine tables and one figure providing inputs for a Markov model, including baseline study characteristics, network meta-analysis results, drug costs, adverse event rates, and utility values. It compares faricimab, administered via a personalized treatment interval, against aflibercept and other treatments from the perspective of the Chinese health system.

Use Cases

• Parameterizing a Markov model for diabetic macular edema treatment cost-effectiveness based on network meta-analysis results.
• Comparing drug administration costs and frequencies for faricimab, aflibercept, and other therapies.
• Analyzing the incidence and cost of complications and adverse events in DME treatment.
• Conducting scenario analyses for health economic models using predefined sensitivity analysis settings.
• Modeling visual acuity (VA) distribution outcomes over a 1-2 year horizon for first and second eyes.

Strengths

• Data is peer-reviewed and published as supplementary material in the Journal of Comparative Effectiveness Research.
• Contains a specific set of nine structured tables covering all major inputs for a health economic model.
• Model population is based on a defined clinical trial subgroup (Chinese subgroup from RHINE trial) with a mean starting age of 58.7 years.

Limitations

• Exact row counts and column names are not provided, limiting precise assessment of dataset scale and structure.
• License (CC-BY-NC-ND-4.0) prohibits commercial use and derivatives, restricting adaptation for some research.
• Primary data format is DOCX, which may require extraction for computational analysis compared to structured formats like CSV.

Provenance

Source

Supplementary materials for the article 'Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China'.

Collection Method

Derived from a network meta-analysis and cost-effectiveness modeling study.

Time Range

Model simulates long-term outcomes; specific time range of underlying clinical data is not stated.

Freshness

Last updated 2026-03-19.

Geography

China (Chinese health system perspective, Chinese subgroup from RHINE trial).